NZ577442A - Arylsulfonamide compounds - Google Patents

Arylsulfonamide compounds

Info

Publication number
NZ577442A
NZ577442A NZ577442A NZ57744207A NZ577442A NZ 577442 A NZ577442 A NZ 577442A NZ 577442 A NZ577442 A NZ 577442A NZ 57744207 A NZ57744207 A NZ 57744207A NZ 577442 A NZ577442 A NZ 577442A
Authority
NZ
New Zealand
Prior art keywords
compound
raryl
compound according
alkyl
rheteroaryl
Prior art date
Application number
NZ577442A
Other languages
English (en)
Inventor
Jonathan Bayldon Baell
Guillaume Laurent Lessene
Brad Edmund Sleebs
Wayne J Fairbrother
John A Flygare
Michael F Koehler
Original Assignee
Genentech Inc
Inst Medical W & E Hall
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Inst Medical W & E Hall filed Critical Genentech Inc
Publication of NZ577442A publication Critical patent/NZ577442A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NZ577442A 2006-11-15 2007-11-15 Arylsulfonamide compounds NZ577442A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85931506P 2006-11-15 2006-11-15
PCT/US2007/084873 WO2008061208A2 (en) 2006-11-15 2007-11-15 Arylsulfonamide compounds

Publications (1)

Publication Number Publication Date
NZ577442A true NZ577442A (en) 2012-02-24

Family

ID=39276199

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ577442A NZ577442A (en) 2006-11-15 2007-11-15 Arylsulfonamide compounds

Country Status (9)

Country Link
US (1) US8168645B2 (OSRAM)
EP (1) EP2094672B1 (OSRAM)
JP (1) JP5366817B2 (OSRAM)
CN (1) CN101535280B (OSRAM)
AU (1) AU2007319209B2 (OSRAM)
CA (1) CA2666837C (OSRAM)
ES (1) ES2423029T3 (OSRAM)
NZ (1) NZ577442A (OSRAM)
WO (1) WO2008061208A2 (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120156134A1 (en) 2007-12-20 2012-06-21 Shayne Squires Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease
EA019156B1 (ru) 2008-02-01 2014-01-30 Такеда Фармасьютикал Компани Лимитед Производные оксима в качестве ингибиторов hsp90
US20110098305A1 (en) * 2008-05-21 2011-04-28 Jonathan Bayldon Baell Arylsulfonamide compounds, compositions and methods of use
US8168784B2 (en) * 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
MX2012003007A (es) * 2009-09-10 2012-04-11 Novartis Ag Sulfonamidas como inhibidores de las proteinas de la familia bcl-2 para el tratamiento de cancer.
TWI535712B (zh) * 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
US20140189897A1 (en) 2011-06-21 2014-07-03 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
BR112014014529A2 (pt) 2011-12-13 2019-09-24 Buck Inst For Res On Aging métodos para melhorar terapias médicas
AU2012355613A1 (en) 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
EA201491264A1 (ru) 2011-12-23 2014-11-28 Новартис Аг Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию
US20150064137A1 (en) 2012-04-17 2015-03-05 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
US9901081B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse for determining the role of senescent cells in cancer
US9901080B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
US20190269675A1 (en) 2014-01-28 2019-09-05 Buck Institute for Research and Aging Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents
WO2015116735A1 (en) 2014-01-28 2015-08-06 Mayo Foundation For Medical Education And Research Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
CA2939121C (en) 2014-01-28 2020-11-24 Mayo Foundation For Medical Education And Research Effective treatment of osteoarthritis, pulmonary disease, ophthalmic disease, and atherosclerosis by removing senescent cells at the site of the disease
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
JOP20190191A1 (ar) 2017-02-22 2019-08-08 Astrazeneca Ab وحدات شجرية علاجية
AU2019207616A1 (en) 2018-01-10 2020-07-09 Recurium Ip Holdings, Llc Benzamide compounds
CN108276395B (zh) * 2018-02-09 2021-02-26 合肥华方医药科技有限公司 一种多沙唑嗪杂质的制备方法
CN108570039B (zh) * 2018-04-25 2022-09-23 上海美迪西生物医药股份有限公司 一类具有抑制抗凋亡蛋白活性的化合物及其制备和应用
CN109851535A (zh) * 2019-01-30 2019-06-07 天津现代职业技术学院 一种制备4-氟-3-(三氟甲磺酰基)苯磺酰胺的方法
CN113248415B (zh) * 2021-05-26 2022-08-09 苏州正永生物医药有限公司 一种abt-737关键中间体的制备方法以及abt-737的制备方法
CA3237199A1 (en) 2021-11-02 2023-05-11 Flare Therapeutics Inc. Pparg inverse agonists and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6720338B2 (en) 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
MXPA04009141A (es) * 2002-03-21 2004-11-26 Abbott Lab Promotores de apoptosis, de n-sulfonilurea.
WO2005049593A2 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7642260B2 (en) * 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
US8614318B2 (en) * 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
US7767684B2 (en) * 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
JP4826256B2 (ja) 2003-11-20 2011-11-30 三菱瓦斯化学株式会社 液状シクロヘキサントリカルボン酸無水物
WO2005117543A2 (en) * 2004-05-26 2005-12-15 Abbott Laboratories N-sulfonylcarboximidamide apoptosis promoters
KR20070046180A (ko) * 2004-08-20 2007-05-02 더 리젠츠 오브 더 유니버시티 오브 미시간 항세포사멸 ｂｃｌ-2군 구성원의 소분자 억제제 및 이의용도
US20060122247A1 (en) * 2004-12-08 2006-06-08 Solvay Pharmaceuticals B.V. Aryloxyethylamine and phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition
DK1888550T3 (da) * 2005-05-12 2014-09-29 Abbvie Bahamas Ltd Apoptosepromotorer

Also Published As

Publication number Publication date
EP2094672A2 (en) 2009-09-02
EP2094672B1 (en) 2013-05-29
ES2423029T3 (es) 2013-09-17
CA2666837C (en) 2015-01-13
US8168645B2 (en) 2012-05-01
CN101535280A (zh) 2009-09-16
CN101535280B (zh) 2012-06-27
WO2008061208A2 (en) 2008-05-22
CA2666837A1 (en) 2008-05-22
HK1134283A1 (en) 2010-04-23
JP2010510237A (ja) 2010-04-02
AU2007319209B2 (en) 2012-04-19
JP5366817B2 (ja) 2013-12-11
WO2008061208A3 (en) 2008-07-03
AU2007319209A1 (en) 2008-05-22
US20100056517A1 (en) 2010-03-04

Similar Documents

Publication Publication Date Title
CA2666837C (en) Arylsulfonamide compounds
ES2967983T3 (es) Compuestos
WO2017101803A1 (zh) 一种新型egfr和alk激酶的双重抑制剂
US20100197711A1 (en) Benzothiazole compounds
US20090030197A1 (en) Quinoline Intermediates of Receptor Tyrosine Kinase Inhibitors and the Synthesis Thereof
US10421743B2 (en) Tetrahydroisoquinolines as PRMT5 inhibitors
KR20050044599A (ko) Ｅｇｆ-ｒ 및 ｈｅｒ2 키나아제의 억제제로서의3-시아노퀴놀린
AU2019218187B2 (en) Dioxinoquinoline compounds, preparation method and uses thereof
AU2018226922B2 (en) Urea-substituted aromatic ring-linked dioxane-quinazoline and -linked dioxane-quinoline compounds, preparation method therefor and use thereof
TW201418220A (zh) 新的喹啉類化合物及其用途
Altıntop et al. Synthesis and evaluation of a series of 1, 3, 4-thiadiazole derivatives as potential anticancer agents
CA2871453A1 (en) Quinazolinedione derivative
TW200838531A (en) New aniline or phenol mustrads linked to DNA-affinic molecules or water-soluble aromatic rings and their use as cancer
WO2019170088A1 (zh) 一种噁嗪并喹唑啉与噁嗪并喹啉类化合物及其制备方法和应用
JP5227179B2 (ja) ３，６−ジヒドロ−２−オキソ−６ｈ−１，３，４−チアジアジン誘導体
US20090264427A1 (en) 3-Cyanoquinolines, Methods for Preparation and Use as Insulin-like Growth Factor Inhibitors
ES2328929T3 (es) Dihidroquinazolinas 2-sustituidas.
Brzozowski et al. Carbonic anhydrase inhibitors. Regioselective synthesis of novel series 1-substituted 1, 4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII
JP7022454B2 (ja) ジオキシノキノリン系化合物、その調製方法および使用
HK1134283B (en) Arylsulfonamide compounds
CN111440177B (zh) 一种取代吡唑并[1,5-a]嘧啶类化合物及其制备方法和应用
WO2025010279A2 (en) Polo-like kinase 1 inhibitors
CN117486813A (zh) N-二取代苯基丙烯酰胺类化合物及其药物组合物和用途
HK40042713B (en) Oxazino-quinazoline and oxazino-quinazoline type compound, preparation method therefor, and uses thereof
HK40042713A (en) Oxazino-quinazoline and oxazino-quinazoline type compound, preparation method therefor, and uses thereof

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 15 NOV 2017 BY THOMSON REUTERS

Effective date: 20140912

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 NOV 2018 BY THOMSON REUTERS

Effective date: 20171012

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 NOV 2019 BY THOMSON REUTERS

Effective date: 20181018

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 NOV 2020 BY THOMSON REUTERS

Effective date: 20191017

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 NOV 2021 BY THOMSON REUTERS

Effective date: 20200926

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 NOV 2022 BY THOMSON REUTERS

Effective date: 20211002

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 NOV 2023 BY THOMSON REUTERS

Effective date: 20221003

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 NOV 2024 BY ANAQUA SERVICES

Effective date: 20231020

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 NOV 2025 BY ANAQUA SERVICES

Effective date: 20241022

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 NOV 2026 BY ANAQUA SERVICES

Effective date: 20251022